ABSTRACT. To determine the effects of fetal 8-2 agonist fetal lambs results in increased serum glucose levels with elevaexposure on fetal hepatic glycogen metabolism, we infused tion of serum lactate and pyruvate concentrations, and attributed ritodrine at a rate of 1.3 f 0.4 pg/kg/min (mean f SD) for these effects to increased glycolysis. 24 h into six chronically catheterized twin fetal lambs Hepatic glycogen deposition and mobilization are regulated starting between 128 and 134 days gestation. The control by the relative activities of glycogen synthase and glycogen twins received 0.9% saline at 1.2 f 0.12 mllkglh. In phosphorylase, which are in turn regulated by phosphorylase addition, 15 uncatheterized fetuses were killed between kinase and protein phosphatase-1 (7). Phosphorylation of glyco-115 and 148 days gestation as unoperated controls. Rito-gen phosphorylase by phosphorylase kinase activates glycogen drine infusion produced a 1.7-fold elevation in fetal serum phosphorylase, thereby increasing the rate of biodegradation of glucose level, from 23 f 5 to 42 f 15 mgldl, and a 2-fold glycogen. In contrast, phosphorylation of glycogen synthase by elevation in serum insulin level, from 16 f 5 to 34 f 8 mg/ phosphorylase kinase deactivates glycogen synthase, thereby deml, p < 0.01. Hepatic glycogen content increased 7-fold in creasing the rate of glycogen biosynthesis. Protein phosphatasethe uncatheterized controls between 115 and 148 days 1 dephosphorylates glycogen phosphorylase and glycogen syngestation (r = 0.9, p < 0.001). Ritodrine infusion reduced thase, respectively, decreasing and increasing enzyme activity.
the uncatheterized controls between 115 and 148 days 1 dephosphorylates glycogen phosphorylase and glycogen syngestation (r = 0.9, p < 0.001). Ritodrine infusion reduced thase, respectively, decreasing and increasing enzyme activity.
hepatic glycogen content by 50% from 179 f 19 pglmg in
The purpose of our study was to determine the effects of fetal twin controls to 90 f 25 pglmg in the ritodrine-infused ritodrine exposure on hepatic glycogen metabolism. twins, p < 0.001. Hepatic glycogen phosphorylase kinase activity was elevated 1.3-fold from 0.149 + 0.100 mU/mg protein in control twins to 0.186 f 0.007 mU/mg protein MATERIALS AND METHODS in the ritodrine infused twins, P < 0.001. Glycogen ~h o s -Animalpreparation. Between 120 and 124 days gestation (term ~h o r~l a s e a activity was also increased 1.4-fold from 8-60 is 148 days), six time-dated pregnant ewes were operated on 0.76 nM NADPH/minlmg protein in twins under epidural anesthesia as described previously in detail (8). 11.85 f 0.68 nM NADPHIminlmg protein in the ritodrine Catheters were placed in a fetal carotid artery, jugular vein, and infused twins, p < 0.001. There were no significant differ-the trachea. After the operation the fetuses received 200,000 U ences in hepatic total glycogen phosphorylase (a + b, of penicillin and 10 mg kanamycin intravenously every day, and activity, active (I) or total I + D) glycogen s~nthase activity, the ewes received 1.2 million U of procaine penicillin and 1 g of rotei in, or DNA content between the ritodrine treated and kanamycin intramuscularly daily for 5 days. The fetuses were control twins or between the control twins and the uncath-allowed to rest for 7 days or longer before ritodrine was infused. eterized control fetuses. We conclude that 6-2 agonist Ritodrine infusion. Ritodrine hydrochloride was infused intradepletes hepatic glycogen in fetal lambs through activation venously into one of each pair of twin fetuses at a rate of 1.3 + of glycogen phosphorylase by glycogen ~h o s~h o r~l a s e ki-0.4 pg/kg/min (mean + SD) for 24 h starting between 128 and nase. Depletion of hepatic glycogen may be an unrecog-135 days of gestation. The rate of ritodrine infusion was chosen nized side effect of fetal P-2 agonist exposure. (Pediatr Res to be similar to the rate of administration recommended for 24: 330-332,1988) pregnant women (1, 2) . The other twin served as a control. The infusion vehicle was 0.9% saline and was given at 1.2 k 0.12 ml/ kdh.
Sample collection and analysis. Arterial blood samples (3.0
Beta sympathomimetic drugs are used in obstetric practice to ml; approximately 1 % of fetal blood volume) were obtained inhibit premature labor because of their tocolytic action on every 48 to 72 h up to 127 days gestation and then daily. ~rterial uterine smooth muscle (1, 2). However, neonates born to moth-blood gases were measured at 39" C using a corning 178 blood ers infused with P-agonists may experience hyperinsulinemia and gas analyzer (Corning Medical and Scientific, ~e d f o r d , MA). hypoglycemia (3, 4) .
Serum was separated from the arterial blood and stored at -40" Tenenbaum and Cowett (5) showed that infusion of the P-2 C for subsequent analysis. Serum glucose concentration in mg/ agonist ritodrine into neonatal lambs results in increased glucose dl Was measured by the glucose oxidase method using a Y S I -2 3~ production as well as increased insulin secretion, and speculated glucose Springs Instruments, that the former may be due to hepatic glycogenolysis. However, OH). Serum insulin was measured by double antibody radiosiimes and creasy (6) The pieces were stored at -70" C for subsequent analysis. The P-2 AGONIST DEPLETES FETAL HEPATIC GLYCOGEN 33 1 biochemical assays reported below were consistent and stable over a period of months. In addition, 15 uncatheterized fetuses were sacrificed between 115 and 148 days gestation to provide comparative data on the ontogeny of fetal hepatic glycogen metabolism.
Glycogen phosphorylase activity and glycogen content. Glycogen phosphorylase (EC 2.4.1. l) activity of tissue homogenate was assayed by measuring the rate of NADPH generation using the method of Schwartz et al. (10) . Glycogen content was analyzed by the method of Lowry and Passoneau (1 l) in which NADPH generation from glucose-6-phosphate is measured fluorimetrically.
Glycogen synthase activity. Glycogen synthase (EC 2.4.1.1 1) activity of tissue homogenates was assayed by measuring the incorporation of [I4C]-UDPG glucose into glycogen as described by Eisen et al. (1 2) and Thomas et al. (1 3) .
Phosphorylase kinase activity. Phosphorylase kinase (EC 2.7.1.38) activity of tissue homogenates was assayed following the procedure of Hardie and Cohen (14) , wherein phosphorylase kinase phosphorylates phosphorylase b, activating it to phosphorylase a. Activation of phosphorylase a is then measured in a subsequent incubation by following the release of inorganic phosphate from glucose-1 -phosphate colorirnetrically.
Protein and DNA content. Protein content was measured using the method of Markwell et al. (1 5) using bovine serum albumin as the standard. DNA content was measured using the fluorimetric technique of Erwin et al. (16) .
Statistical methods. Comparisons between the ritodrine treated and control twins were made using the paired t test. A computer modeling technique (Vidichart, Interactive Microware, State College, PA) was used to fit a least squares curve correlation between gestational age and glycogen. Statistical significance was present when p < 0.05. The data are expressed as the mean + SD.
RESULTS
The effects of ritodrine infusion on fetal blood gases and plasma glucose have been published in detail (8) . Briefly, ritodrine infusion was associated with a 1.7-fold elevation in serum glucose level from 23 f 5 to 42 + 15 mg/dl (mean + SD). Serum insulin was elevated 2-fold from 16 f 5 pU/ml in the controls to 34 + 8 pU/ml in the ritodrine infused twins ( p < 0.00 1). Fetal glucose and insulin levels before ritodrine infusion were not significantly different from the corresponding values in the control twins. Fetal hepatic protein and DNA content in the ritodrine-treated fetuses were not significantly different from control values.
The effects of ritodrine on hepatic glycogen content and on the activities of glycogen phosphorylase, glycogen synthase, and phosphorylase kinase are shown in Figures 1-4 .
Hepatic glycogen content in uncatheterized controls increased 7-fold from 38 pg/mg tissue at 1 15 days gestation to 294 pg/mg tissue at 148 days gestation (r = 0.9, p < 0.001). Thus, hepatic glycogen content increased with gestational age during the latter third of fetal lamb gestation. The effects of P-2 agonist were superimposed on this relationship. Hepatic glycogen content in the ritodrine-treated twins, 90 k 25 pg/mg tissue, was reduced 50% in comparison with 179 + 19 pg/mg tissue in the twin controls, p < 0.00 1. Hepatic glycogen content in the twin controls was not different from the uncatheterized fetal hepatic glycogen content at the same period of gestation.
Hepatic glycogen phosphorylase kinase activity in the rito- There were no significant differences in total glycogen phosphorylase (a + b) activity or in active (I) or total (I + D) glycogen synthase activity between the ritodrine treated and the control twins or between the control twins and the uncatheterized control fetuses. Thus, P-2 agonist stimulation depleted fetal hepatic glycogen content by activation of phosphorylase kinase, which in turn increased the fraction of glycogen phosphorylase in the active (a) state.
DISCUSSION
The rate of ritodrine infusion in our study was chosen to be similar to the recommended rate of administration of ritodrine to pregnant women (1, 2) . The effects of this infusion on fetal blood gases, plasma glucose, pulmonary surfactant, lung mechanics, and lung metabolism have been reported previously (8, 17) .
i;lycogen deposition and mobilization are regulated by the relative activities of glycogen phosphorylase and glycogen synthase, which are in turn regulated by the calcium-calmodulindependent enzyme termed phosphorylase kinase (7) . Hepatic glycogen deposits accumulate during fetal life, indicating that the ontogenic regulation of the activities of glycogen phosphorylase and glycogen synthase favors glycogen biosynthesis (10) . However, we report that infusion of ritodrine into fetal lambs between 128 and 135 days gestation results in depletion of hepatic glycogen to levels similar to those seen below 125 days gestation. Thus P-2 agonist stimulation favors glycogen biodegradation in the fetal liver.
Hormones, including glucagon, epinephrine, norepinephrine, and vasopressin, all have been reported to act as physiologic stimuli of hepatic glycogenolysis (1 8). The increased activities of glycogen phosphorylase kinase and of glycogen phosphorylase a in fetal liver homogenates suggest that known /3-adrenergic agonist pathways involving phosphorylation of glycogen phosphorylase were responsible for the depletion of hepatic glycogen (7, 10) . However, glycogen synthase activity was unchanged after 0-2 agonist stimulation. The activity of protein phosphatase-1 was not measured.
Hyperinsulinemia and hypoglycemia have been reported in infants whose mothers received ritodrine infusion shortly before delivery (3, 4) . In our study, fetal ritodrine exposure was associated with fetal hyperglycemia, hyperinsulinemia, and hepatic glycogen depletion. Inasmuch as ritodrine crosses the human placenta (19, 20) , depletion of fetal hepatic glycogen reserves may be an unrecognized side effect of fetal ritodrine exposure.
